Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High-dose Versus Standard-dose Weight-based Ribavirin in Combination With Peginterferon Alfa-2a for Patients Infected With Hepatitis C Virus Genotype 1 or 4

NCT00662220 is registered in ClinicalTrials.gov with Foundation for Liver Research as lead sponsor.

NCT NCT00662220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00662220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High-dose Versus Standard-dose Weight-based Ribavirin in Combination With Peginterferon Alfa-2a for Patients Infected With Hepatitis C Virus Genotype 1 or 4
Lead sponsor
Foundation for Liver Research
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2008
Completion date
November 30, 2013
Enrollment
110 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c